<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02362074</url>
  </required_header>
  <id_info>
    <org_study_id>P14-455</org_study_id>
    <nct_id>NCT02362074</nct_id>
  </id_info>
  <brief_title>Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>P @ Work</acronym>
  <official_title>Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe the impact of treatment with adalimumab on work
      related productivity and economic burden in patients with Rheumatoid Arthritis (RA) treated
      in Canada.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2015</start_date>
  <completion_date type="Actual">March 6, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Rheumatoid Arthritis-Work Instability Scale (RA-WIS)</measure>
    <time_frame>From Month 0 to Month 6</time_frame>
    <description>This is patient-reported assessment on the impact of adalimumab on the work status of RA patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Financial Loss</measure>
    <time_frame>From Month 0 to Month 6</time_frame>
    <description>This is patient reported assessment of financial burden of RA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Rheumatoid Arthritis-Work Instability (RA-WIS)</measure>
    <time_frame>From Month 0 to Month 12, 18 and 24</time_frame>
    <description>This is patient-reported assessment on the impact of adalimumab on the work status of RA patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Financial Loss</measure>
    <time_frame>From Month 0 to Month 12, 18 and 24</time_frame>
    <description>This is patient reported assessment of financial burden of RA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient pain</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>Pain is assessed using Visual Analogue Scale (VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tender Joint Count (TJC)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>This is assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS) 28</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>Disease activity assessment is done by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient assessment of Global Disease Activity</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>It is assessed using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Swollen Joint Count (SJC)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>This is assessed by the physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in physician's assessment of Global Disease Activity</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>It is assessed using VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>This is patient reported functional assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in c-reactive protein (CRP)/erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>CRP/ESR values are measured as an inflammatory parameter. Low CRP and ESR values mean less inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Remission per Disease Activity Scale (DAS) 28</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score less than 2.6 indicates clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Achieving Low Disease Activity (LDA) per Disease Activity Score (DAS) 28</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores range from 0 to 10 with LDA defined as a score from 2.6 to &lt; 3.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Remission Per Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>The CDAI is used to evaluate disease activity in patients with Rheumatoid Arthritis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Achieving Low Disease Activity (LDA) per CDAI</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>The CDAI is a composite index for assessing disease activity. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity. LDA was defined as a score from 2.8 to ≤ 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Remission per Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>The SDAI is a validated measure of rheumatoid arthritis disease activity. Scores on the SDAI range from 0 to 86 with a SDAI score ≤3.3 indicating clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Achieving Low Disease Activity (LDA) per SDAI</measure>
    <time_frame>From Month 0 to Month 24</time_frame>
    <description>The SDAI is a validated measure of rheumatoid arthritis disease activity. Scores on the SDAI range from 0 to 86 with a SDAI score &lt;11 indicating LDA.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">401</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab subjects</arm_group_label>
    <description>Subjects starting Adalimumab treatment at time of enrollment.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This is a Multi-Center Canadian Observational Study that will enroll rheumatoid arthristis
        (RA) subjects for whom the treating physician has decided to treat with adalimumab.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with moderate to severe RA for whom the physician has decided to initiate
             treatment with adalimumab

          2. Adult male or female ≥ 18 years old that has been newly prescribed adalimumab therapy
             according to the local product label and are with PROGRESS

          3. Subjects should be evaluated for tuberculosis (TB) exposure/risk factors for active
             and latent TB

          4. Subject is able to give written patient authorization and is willing to comply with
             the requirements of this study protocol.

        Exclusion Criteria:

          1. Subject cannot or will not sign a patient authorization

          2. Subject with a known hypersensitivity to Adalimumab, or any of its components

          3. Presence of any condition that, in the opinion of the treating physician, prohibits
             the subject from participating in the study or obscures the assessment of the
             treatment of RA

          4. Subjects currently participating in an investigational clinical trial

          5. Subjects treated with &gt;1 prior biologic disease-modifying antirheumatic drugs (DMARDs)
             for RA. Any prior treatment with adalimumab is prohibited

          6. Subjects previously treated with targeted synthetic disease modifying agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pont, Cranbrook, BC, CA /ID# 134511</name>
      <address>
        <city>Cranbrook</city>
        <state>British Columbia</state>
        <zip>V1C 2R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs. M &amp; W Teo Inc. /ID# 148641</name>
      <address>
        <city>Penticton</city>
        <state>British Columbia</state>
        <zip>V2A 4Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Research Center /ID# 147466</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kur, Vancouver, CA /ID# 135371</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic /ID# 134830</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research /ID# 135411</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 5E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clare's Mercy Hospital /ID# 136737</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Juris Lazovskis Inc. /ID# 134510</name>
      <address>
        <city>Sydney</city>
        <state>Nova Scotia</state>
        <zip>B1S 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterside Clinique /ID# 134190</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs Nalin and Vandana Ahluwali /ID# 136485</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Sanjay Dixit Medicine Professional Corporation /ID# 136486</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7L 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Chrisotomor Kouroukis &amp; Dr /ID# 151189</name>
      <address>
        <city>Dundas</city>
        <state>Ontario</state>
        <zip>L9H 1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adachi Medicine Prof. Corp /ID# 152538</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Mountain Medical Center /ID# 134832</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L9C 5N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Martin M.S. Lee Med Prof C /ID# 138333</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 1W4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brandusa Florica Med Prof Corp /ID# 134829</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montgomery, Mississauga, CA /ID# 136943</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology /ID# 134834</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rajwinder S. Dhillon Medicine /ID# 147756</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2E 6A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital North Therapeutics Res /ID# 134835</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setty, Owen Sound, CA /ID# 134189</name>
      <address>
        <city>Owen Sound</city>
        <state>Ontario</state>
        <zip>N4K 1S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Centre /ID# 134833</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 7B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Involved Medicine /ID# 163880</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Samuel K Silverberg /ID# 136496</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Rhum. de Montreal /ID# 135289</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital /ID# 204168</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PSS Medical Inc. /ID# 134193</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Rhumatologie de Montréal /ID# 162186</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4N 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ctr. de Rheum de l'est du QC /ID# 135410</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 8W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheum Disease Ctr of Montreal /ID# 135372</name>
      <address>
        <city>Westmount</city>
        <state>Quebec</state>
        <zip>H3Z 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Latha Naik /ID# 135813</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chuq - Chul /Id# 137054</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://rxabbvie.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 9, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2015</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

